Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia Int J Headache. 2018;38(1):1–211.

Article  Google Scholar 

Bigal ME, Lipton RB. Migraine chronification. Curr Neurol Neurosci Rep. 2011;11(2):139–48.

Article  PubMed  Google Scholar 

Ekbom K, Hardebo JE. Cluster headache: aetiology, diagnosis and management. Drugs. 2002;62(1):61–9.

Article  CAS  PubMed  Google Scholar 

Benoliel R, Eliav E. Primary headache disorders. Dent Clin North Am. 2013;57(3):513–39.

Article  PubMed  Google Scholar 

Robbins MS, Starling AJ, Pringsheim TM, Becker WJ, Schwedt TJ. Treatment of cluster headache: The American Headache Society evidence-based guidelines. Headache. 2016;56(7):1093–106.

Article  PubMed  Google Scholar 

Schindler EAD, Gottschalk CH. Cluster Headache Preventive Therapies. Wayne: Bryn Mawr Communications; 2019.

Google Scholar 

Burch R. Migraine and tension-type headache: diagnosis and treatment. Med Clin North Am. 2019;103(2):215–33.

Article  PubMed  Google Scholar 

Mather PJ, Silberstein SD, Schulman EA, Hopkins MM. The treatment of cluster headache with repetitive intravenous dihydroergotamine. Headache. 1991;31(8):525–32.

Article  CAS  PubMed  Google Scholar 

Magnoux E, Zlotnik G. Outpatient intravenous dihydroergotamine for refractory cluster headache. Headache. 2004;44(3):249–55.

Article  CAS  PubMed  Google Scholar 

Nagy AJ, Gandhi S, Bhola R, Goadsby PJ. Intravenous dihydroergotamine for inpatient management of refractory primary headaches. Neurology. 2011;77(20):1827–32.

Article  CAS  PubMed  Google Scholar 

Edvinsson L. CGRP antibodies as prophylaxis in migraine. Cell. 2018;175(7):1719.

Article  CAS  PubMed  Google Scholar 

Goadsby PJ, Dodick DW, Leone M, Bardos JN, Oakes TM, Millen BA, et al. Trial of galcanezumab in prevention of episodic cluster headache. N Engl J Med. 2019;381(2):132–41.

Article  CAS  PubMed  Google Scholar 

Osmond H. A review of the clinical effects of psychotomimetic agents. Ann N Y Acad Sci. 1957;66(3):418–34.

Article  CAS  PubMed  Google Scholar 

Nichols DE. Psychedelics. Pharmacol Rev. 2016;68(2):264–355.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McGeeney BE. Cannabinoids and hallucinogens for headache. Headache. 2013;53(3):447–58.

Article  PubMed  Google Scholar 

Sewell RA, Halpern JH, Pope HG Jr. Response of cluster headache to psilocybin and LSD. Neurology. 2006;66(12):1920–2.

Article  PubMed  Google Scholar 

Sewell RA, Gottschalk CH. Problem child is no headache. Headache. 2011;51(2):306 (author reply -7).

Article  PubMed  Google Scholar 

Schindler EA, Gottschalk CH, Weil MJ, Shapiro RE, Wright DA, Sewell RA. Indoleamine hallucinogens in cluster headache: results of the Clusterbusters Medication Use survey. J Psychoactive Drugs. 2015;47(5):372–81.

Article  PubMed  Google Scholar 

Burish MJ, Pearson SM, Shapiro RE, Zhang W, Schor LI. Cluster headache is one of the most intensely painful human conditions: Results from the International Cluster Headache Questionnaire. Headache. 2021;61(1):117–24.

Article  PubMed  Google Scholar 

Schindler EAD, Cooper V, Quine DB, Fenton BT, Wright DA, Weil MJ, et al. “You will eat shoe polish if you think it would help”-Familiar and lesser-known themes identified from mixed-methods analysis of a cluster headache survey. Headache. 2021;61(2):318–28.

Article  PubMed  Google Scholar 

Kempner J. Psychedelic outlaws : the movement revolutionizing modern medicine. 1st ed. New York: Hachette Books; 2024.

Google Scholar 

Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Zhu Y, et al. Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double-blind, placebo-controlled trial. Headache. 2022;62(10):1383–94.

Article  PubMed  Google Scholar 

Schindler EAD, Sewell RA, Gottschalk CH, Flynn LT, Zhou Y, Pittman BP, et al. Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial. J Neurol Sci. 2024;460:122993.

Madsen MK, Petersen AS, Stenbaek DS, Sorensen IM, Schionning H, Fjeld T, et al. CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity. Headache. 2024;64(1):55–67.

Article  PubMed  Google Scholar 

Koehler PJ, Tfelt-Hansen PC. History of methysergide in migraine. Cephalalgia Int J Headache. 2008;28(11):1126–35.

Article  CAS  Google Scholar 

Sicuteri F. Prophylactic treatment of migraine by means of lysergic acid derivatives. Triangle Sandoz J Med Sci. 1963;6:116–25.

CAS  Google Scholar 

Andersson M, Persson M, Kjellgren A. Psychoactive substances as a last resort-a qualitative study of self-treatment of migraine and cluster headaches. Harm Reduct J. 2017;14(1):60.

Article  PubMed  PubMed Central  Google Scholar 

Migrainebusters. Psilocybin and Migraine Disease. 2023 [cited; Available from: https://survey.zohopublic.com/zs/pqz7BQ. Accessed 8 Apr 2024

Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Lindsey H, et al. Exploratory controlled study of the migraine-suppressing effects of psilocybin. Neurotherapeutics. 2021;18(1):534–43.

Article  CAS  PubMed  Google Scholar 

Schindler EAD. The potential of psychedelics for the treatment of episodic migraine. Curr Pain Headache Rep. 2023;27(9):489–95.

Article  PubMed  Google Scholar 

Karst M, Halpern JH, Bernateck M, Passie T. The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: an open, non-randomized case series. Cephalalgia Int J Headache. 2010;30(9):1140–4.

Article  Google Scholar 

Nichols DE, Nichols CD. Serotonin receptors. Chem Rev. 2008;108(5):1614–41.

Article  CAS  PubMed  Google Scholar 

Schindler EAD, Hendricks PS. Adapting psychedelic medicine for headache and chronic pain disorders. Expert Rev Neurother. 2023;23(10):867–82.

Article  CAS  PubMed  Google Scholar 

Schindler EAD. Psychedelics as preventive treatment in headache and chronic pain disorders. Neuropharmacology. 2022;1(215): 109166.

Article  Google Scholar 

Lodge D, Mercier MS. Ketamine and phencyclidine: the good, the bad and the unexpected. Br J Pharmacol. 2015;172(17):4254–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am J Psychiatry. 2021;178(5):383–99.

Article  PubMed  PubMed Central  Google Scholar 

Cohen SP, Bhatia A, Buvanendran A, Schwenk ES, Wasan AD, Hurley RW, et al. Consensus guidelines on the use of intravenous ketamine infusions for chronic pain from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018;43(5):521–46.

CAS  PubMed  PubMed Central